HAE as reported
Haemonetics Corporation reported $1.33B of revenue over the trailing twelve months, −2.0% on the year before. 11 reported series are charted on this page, each one as filed.
$1.33B
Revenue, trailing twelve months · to Q4 2026 · −2.0% against the twelve months before
- Net Income
- $97M
Net Income · −42% year on year · trailing twelve months to Q4 2026
- Free Cash Flow
- $260M
Free Cash Flow · +83% year on year · trailing twelve months to Q4 2026
- Op Margin
- 12%
Op Margin · trailing twelve months to Q4 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.33B | −2.0% | Q4 2026 |
| Net Income | $97M | −42% | Q4 2026 |
| EPS | $2.05 | −38% | Q4 2026 |
| Gross Margin | 59% | n/a | Q4 2026 |
| Op Margin | 12% | n/a | Q4 2026 |
| Net Margin | 7.4% | n/a | Q4 2026 |
| ROE | 17% | n/a | Q4 2026 |
| ROA | 6.2% | n/a | Q4 2026 |
| ROIC | 9.8% | n/a | Q4 2026 |
| Free Cash Flow | $260M | +83% | Q4 2026 |
| P/E | 52.0 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Haemonetics Corporation (HAE) - Revenue & ProfitRevenue & ProfitHaemonetics Corporation (HAE)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com